诺和诺德(NVO.US)潜力减肥药中国中期试验告捷，减重近20%

Group 1 - The core finding of the mid-stage study in China indicates that the experimental drug developed by Novo Nordisk shows significant weight loss effects, with participants losing up to 19.7% of their body weight after 24 weeks, compared to only 2% for those on a placebo [1] - The trial involved 205 patients who were randomly assigned to receive doses of 2mg, 4mg, or 6mg of the drug or a placebo, with results based on estimated outcomes if all patients adhered to the treatment plan [1] - Novo Nordisk plans to conduct its own global early clinical trials for the drug and expects to release primary data by 2027, expressing encouragement regarding the data from the Chinese trial [1] Group 2 - The candidate drug UBT251 is a long-acting synthetic peptide triple agonist targeting GLP-1, GIP, and glucagon receptors, potentially making it more effective than Novo Nordisk's Wegovy, which only targets GLP-1 [2] - Under the licensing agreement, Novo Nordisk will obtain development, manufacturing, and commercialization rights for UBT251 outside of mainland China, Hong Kong, Macau, and Taiwan, while United Biotechnology retains rights in those regions [2] - United Biotechnology is eligible for a $200 million upfront payment, up to $1.8 billion in potential milestone payments, and tiered sales royalties as part of the agreement [2] Group 3 - Based on the mid-stage study results, International Laboratories will also initiate Phase 3 clinical trials for the drug in China [3]